SG Americas Securities LLC Invests $142,000 in C4 Therapeutics, Inc. (NASDAQ:CCCC)

SG Americas Securities LLC bought a new stake in C4 Therapeutics, Inc. (NASDAQ:CCCC) during the third quarter, Holdings Channel reports. The fund bought 24,941 shares of the company’s stock, valued at approximately $142,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of C4 Therapeutics in the 1st quarter worth about $339,000. Susquehanna Fundamental Investments LLC acquired a new position in C4 Therapeutics during the first quarter valued at approximately $420,000. Entropy Technologies LP purchased a new stake in C4 Therapeutics during the first quarter worth approximately $126,000. Vanguard Group Inc. increased its position in shares of C4 Therapeutics by 46.0% in the first quarter. Vanguard Group Inc. now owns 2,920,028 shares of the company’s stock worth $23,857,000 after acquiring an additional 920,627 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new position in shares of C4 Therapeutics in the 1st quarter valued at $233,000. Hedge funds and other institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Stock Down 1.0 %

CCCC opened at $5.89 on Friday. The firm’s 50 day moving average is $6.06 and its 200-day moving average is $5.88. C4 Therapeutics, Inc. has a 52-week low of $1.06 and a 52-week high of $11.88. The firm has a market capitalization of $405.27 million, a P/E ratio of -2.49 and a beta of 3.04.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.11. C4 Therapeutics had a negative net margin of 367.17% and a negative return on equity of 44.60%. The business had revenue of $12.01 million during the quarter, compared to analyst estimates of $6.88 million. Equities analysts expect that C4 Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, BMO Capital Markets reaffirmed an “outperform” rating and set a $20.00 price target on shares of C4 Therapeutics in a research report on Tuesday, August 6th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.50.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.